We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting FLT3Mutations in AcuteMyeloid Leukemia.
- Authors
El Fakih, Riad; Rasheed, Walid; Hawsawi, Yousef; Alsermani, Maamoun; Hassanein, Mona
- Abstract
The FMS-like tyrosine kinase 3 (FLT3) pathway has an important role in cellular proliferation, survival, and differentiation. Acute myeloid leukemia (AML) patients with mutated FLT3 have a large disease burden at presentation and a dismal prognosis. A number of FLT3 inhibitors have been developed over the years. The first-generation inhibitors are largely non-specific, while the second-generation inhibitors are more specific and more potent. These inhibitors are used to treat patients with FLT3-mutated AML in virtually all disease settings including induction, consolidation, maintenance, relapse, and after hematopoietic cell transplantation (HCT). In this article, we will review the use of FLT3 inhibitors in AML.
- Subjects
ACUTE myeloid leukemia treatment; PROTEIN-tyrosine kinase inhibitors; GENETIC mutation; HEMATOPOIETIC stem cell transplantation; DISEASE relapse
- Publication
Cells (2073-4409), 2018, Vol 7, Issue 1, p4
- ISSN
2073-4409
- Publication type
Article
- DOI
10.3390/cells7010004